INTRODUCTION
Critically ill patients often present stress-induced hyperglycemia due to significant stress-induced insulin resistance. Hyperglycemia worsens outcomes and increases mortality [1] [2] [3] [4] . Effective glycemic control should reduce blood glucose (BG) levels, reduce variability and account for inter-and intrapatient variability and evolving physiological patient condition [5] [6] [7] . Some studies have shown that tight glycemic control (TGC) can reduce mortality up to 45% and significantly reduce negative outcomes linked to hyperglycemia [8] [9] [10] . However, achieving these outcomes has been difficult to reproduce [11] [12] [13] in the variable and dynamic critical care patient.
Hypoglycemia is a major risk associated with TGC [3, 14, 15] . Limiting hypoglycemia and ensuring safety is critical for any TGC protocol. However, its occurrence is exacerbated by patient variability and only one study reduced hypoglycemia with TGC [10] . BG measurement frequency also varies significantly across reported studies, from 1 to 4 hours, where longer intervals can lead to greater glycemic variability and hypoglycemia [16, 17] . Model-based controllers using computer models of patient physiology can enable a TGC protocol to capture the patient-specific response to insulin and nutrition inputs and account for patient-specific dynamics to optimize interventions and BG levels [7, [17] [18] [19] [20] .
The STAR (Stochastic TARgeted) model-based controller presented in this paper is a framework that enables adaptive, patient-specific TGC. The STAR protocol directly accounts for evolving physiological patient condition and intra-patient variability by identifying insulin sensitivity (SI) changes at each intervention and using a stochastic model of its future potential variability [6, 7] to optimize control and maximize safety. Because STAR is a model-based approach it can be customized for clinically specified glycemic targets, control approaches (e.g. insulin only, insulin and nutrition, etc.) and clinical resources (measurement frequency). This paper presents a STAR protocol modulating insulin infusions only towards a target glycemia of 125 mg/dL per clinical practice in the trial ICU, and the initial pilot trial results of the protocol. This pilot trial also tested the ability to adapt the model-based STAR TGC framework from its development environment at Christchurch Hospital in New Zealand to a completely separate institute in Liege, Belgium. Specifically, the following areas of control design and performance were explored:
• Control of BG in post-surgical patients by modulating insulin infusions only. This is a departure from previous use of this model in a heterogeneous ICU cohort, using primarily the bolus route to introduce exogenous insulin, while also explicitly modulating nutritional inputs for glycemic control.
• Real-time model prediction performance in clinical trial in an ICU with different clinical practices and patient populations from Christchurch, NZ.
• Suitability of the applied stochastic model to this Belgian group of patients. In particular, were the stochastic models generated from a heterogeneous ICU population over all patient days applicable, or were more specialized stochastic models required?
METHOD

STAR-Liege Protocol
The STAR-Liege protocol presented is customized in glycemic target (125 mg/dL) and control interventions (insulin-only via infusions) to match clinical standards at CHU of Liege (Belgium). If necessary, it raises nutrition rates to avoid hypoglycemia when no exogenous insulin is being given. The time interval between BG measurements is also determined by the protocol, with intervals of 1 and 2 hours for this pilot study. The step-by-step description of this protocol is illustrated in Figure 1 and the insulin rate is calculated as follows:
1. Previous and current blood glucose measurements are used to identify a patient-specific current SI parameter value for the prior time interval [21] . This step accounts for inter-patient variability [17, 22, 23] .
2. For a given patient, insulin sensitivity is quite variable over time (even hour to hour variation of SI parameter value can be important). The stochastic model [6, 7] provides a distribution of possible SI parameter values for the next 1-2 hours and accounts for intra-patient variability.
This New Zealand patient-based stochastic model was assumed to be broadly applicable to Belgian patients as hour-to-hour insulin sensitivity variability in retrospective comparison is similar [5] .
3. The target BG value for the next 1-2 hour interval is defined from the current BG levels ( ) by:
where reductions of 15% per interval are targeted until the target of 125 mg/dL is achieved.
4. The insulin rate required to achieve this BG target is computed with a bisection method using a clinically validated insulin-glucose system model [23] [24] [25] and the median (50 th percentile) expected SI value over the next 1-2 hours, obtained from the stochastic model distribution [6, 7] . Note that the median value is the same as the current SI (no change) at all levels [6, 7] . A maximum insulin rate of 6 U/h is prescribed for safety and to avoid insulin saturation effects [26, 27] . Similarly, the insulin rate rise per intervention is limited to +1U/h if the previous insulin rate is < 1U/h and to +2U/h otherwise to avoid over responding to sudden changes or larger sensor errors. To reduce nursing staff workload associated with making small and frequent changes in insulin rates and thus improve clinical implementation, insulin rates were limited to specific values of (0.0, 0.5, 1.0, 1.3, 1.5, 1.8, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0) U/hour.
Initial situation
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Step 7 A desired 6.25 g/hour default enteral nutrition rate is requested, based on [28] , but nutrition administration is left to the attending clinician. There is typically no parenteral nutrition, unless clinically specified otherwise. To prevent unintended hypoglycemia, enteral and parenteral nutrition rates can be increased by 10% when BG ≤ 108 mg/dL and no insulin has been given or recommended. In this case, the nutrition rates are increased only until the next blood glucose measurement, but can be maintained if required.
The protocol specifies hourly BG measurement, but measurement frequency is decreased by going to a 120-minute interval when the patient is glycemically stable. Stability is defined here as occurring when the current and last three BG measurements are between 90 mg/dl and 139.5 mg/dl. These relatively short 1-2 hour intervals are used to avoid drift during longer intervals [16] . They also match those used in all or part of other protocols (e.g. [10, 11, 19] ), as well as ensuring safety in this proofof-concept pilot trial.
Pilot Trial and Patients
The STAR-Liege protocol was tested in July 2010 at the Centre Hospitalier Universitaire (CHU) in Liège, Belgium. The pilot trial was 24 hours long and included 9 primarily cardiovascular or cardiac surgery (7) patients from the hospital's intensive care units, 3 patients (Patients 2, 3 and 6) were in the first 24 hours post-surgery. Patients were recruited when they had initial blood glucose levels > 145 mg/dL. Table 1 shows the patient details. Ethical consent was granted by the Comité d'éthique hospitalo-facultaire de l'Universitaire de Liège (B70720108843) for the performance of this trial and the audit, analysis and publication of these data.
For each patient, the trial started with a BG measurement made by nursing staff. BG measurements were made using Accu-Chek Inform (Roche Diagnostics, Mannheim, Germany) glucometers. The protocol then calculated a new insulin infusion rate, which was then given by the nurse. The time interval until the next BG measurement is also specified. This clinical procedure is shown in Figure 2 . 
Patient bedside Protocol (on computer)
BG measurement by nurse 
Stochastic Models
The goal of a stochastic model is to describe the hourly variations of the insulin sensitivity. A stochastic model is based on clinically observed insulin sensitivity variations in ICU population data (for more information, refer to appendix). These clinical data can come from a specific type of patients and can be selected in function of the patient days of stay.
The stochastic model initially used in the trial was that of Lin et al. [6, 7] based on all types of patients included in the SPRINT 1 glucose control study and all patient days of stay. However, post-operative cardiac surgery patients in the first few post-operative days have recently been found, based on the results of this pilot study, to potentially be as much as two times more variable in their insulin sensitivity than this broader cohort [unpublished] . Hence, new stochastic models using data from cardiacsurgery patients were generated to better account for this variability and for post-trial assessment of its impact on the clinical results.
Eight new stochastic models are defined, as shown in Table 2 . Each new stochastic model is based on different clinical data sets characterized by three features:
1. the study group: clinical data can come from patients included in the SPRINT study or in the Glucontrol study 2 (or both); 2. the type of patients: clinical data can come from all patients included in the previous selected study(ies), or from a specific type of patients (cardiac-surgery or not cardiac surgery patients);
3. the days of stay: clinical data can come from all days or specific day(s) of patient's ICU stay.
Models 1 to 6 use data from specific days and cohorts to better match the enhanced variability observed clinically in these specific pilot trial cardiac-surgery patients. Models 7 and 8 are based on a parameter modification in the generation of the original stochastic model [30] . More precisely, the variance of each data point of the hourly changes in distribution (each couple ( , = , , +1 = )) is modified compared with the original model. These models are assessed using the clinical data from this trial. Forecasting performance is assessed by the number of clinical results falling in an interquartile range (denoted as IQR, 50% confidence interval band) and 90% confidence interval band (expect ~50% and ~90%). The different stochastic models are also assessed in clinically validated virtual trial re-simulations [23] of the trial to determine the potential impact on interventions given and glycemic outcomes.
RESULTS
Clinical Trial Results -Blood Glucose Control Performance
Clinical results are summarized by whole cohort and per-patient statistics in Table 3 . There were 205 BG measurements taken during 215 hours of control. Hence, primarily 1-hour measurements were specified by the STAR-Liege protocol. This result can also be seen in the individual patient results in Table 3 for the cohort, and the 25%-75% confidence interval across patients in Figure   3 . Note that the slope of the per-patient BG cumulative distribution function (CDF) median is slightly steeper at low BG, so that BG levels are skewed toward higher values as expected with this stochastic model driven approach, as well as for short pilot trial with high initial BG values. Table 3 shows that 45.4% of BG measurements are between 110 and 140 mg/dL and the control is tight in this band, as illustrated by the steep slope of BG CDF for the whole cohort in Figure 4 and similar per-patient CDFs in Figure 3 . A total of 70% of measurements are between 110 and 160 mg/dL, which is largely due to the short length of trial where 8-17 % of total trial time was spent reducing initial BG levels to 140 mg/dL (Table 3) . Thus, the pilot trial length wasn't sufficient to achieve consistently high percentages of BG levels in a tight band around the target. In addition, patient variability played a role in the further time spent with BG > 140 mg/dL. Importantly for safety, Tables 3 and 4 show that there was no severe hypoglycemic measurement (BG < 40 mg/dL). The minimum value reached was 63 mg/dL (Patient 1). Hence, the STAR approach reduced BG levels safely without hypoglycemia. More specifically, STAR guarantees a maximum risk of 5% for BG < 72 mg/dL by design, where these initial results show 1 out of 205 measurements (0.5%).
Finally, nurses only overrode 9 (4.4 %) of the 205 interventions recommended, usually to give a slightly lower insulin dose, indicating good overall compliance. The CDF in Figure 4 shows that no insulin is given in 25% of controller interventions, and that insulin rates varied over the full range allowed. Only 25% of insulin rates are higher than 3.2 U/hour, but more than half of the patients received the maximum allowable insulin rate of 6 U/hour at least once during the 24-hour trial (Patients 1, 4, 7, 8 and 9 , Table 4 ). These results indicate the significant intraand inter-patient variability in insulin sensitivity encountered, which was initially unexpected from the cohort-based stochastic model. They might also be expected in part, as 3 of the patients were in an acute post-surgical (first day) phase ( Table 1) 
Clinical Results -Model Control Performance
Control performance relies directly on the model's prediction ability. Table 5 shows that the average prediction error is 13.9 mg/dl (10.5%). To reduce this error, the system model has to be improved by revisiting the fundamental model structure or the population parameters. However, forecasts within stochastically defined prediction ranges (5%-95% and 25%-75%) are lower than expected (71.6% and 26.1%, instead of 90% and 50%, respectively). This result shows that this group of patients had significantly increased variability in insulin sensitivity compared to the stochastic model used to guide control [7] , which was also similar to a prior analysis over 200 CHU patients over all days of stay [5] .
Therefore, to make improvements about forecasting, the original stochastic model needs to be more specific. 
Stochastic Model Assessment -Virtual Trial Results
This section analyses the changes due to the incorporation of different stochastic models representing cardiac-surgery post-operative patients ( Table 2 ). Virtual trial [16, 17, 23] was performed using the eight new stochastic models of Table 2 to better assess the increased variability in insulin sensitivity observed.
The original stochastic model, based on all SPRINT patients over their entire ICU stay and used during clinical pilot trial, had only 71.6% of forecasts within 5%-95% and 26.1% within 25%-75% (Table   5 ). Among the proposed models in The potential impact of control performance of using a more specialized stochastic model was investi- 
Table 8 -Re-run virtual trial analysis results: per-patient statistics (presented as median [IQR])
Differences between the clinical data and simulations using the original stochastic model arise from different nursing interventions and ability of the simulation environment to replicate the clinical trial [23] . During the pilot trial, slightly less insulin than specified by the controller was administered to patients in some cases if the nurses chose to override the recommendations (9 of 205, 4.4%), which explains the slightly higher BG levels for the clinical data. The difference in trial length and number of BG measurements in the simulated trial can be attributed to delays in BG measurements in the clinical environment and subsequent rounding of intervention times (where the simulated controller would take measurements on the hour). However, with respect to glycemic outcome, these differences are not clinically significant. Patient  Clinical data  Clinical trial re-simulated as  per-protocol  Clinical data  Clinical trial re-simulated as  per-protocol   1  24  23  22  21   2  23  22  19  18   3  23  22  22  21   4  23  22  24  23   5  26  26  24  24   6  24  23  24  23   7  23  22  24  23   8  24  23  22  21   9  25  25 24 24
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Table 9 -Comparison between clinical data and clinical virtual trials re-simulated as per-protocol in terms of number of measurements and trial length
It is observed in Tables 7-9 that there is no real difference in measurement frequency using the new Model 5 stochastic model. It is also seen that patients received more insulin (~ 30%) in re-simulated trial, especially with Model 5. This result explains the lower BG levels associated with Model 5 in Table 8 and in the BG CDFs shifting to slightly lower BG values in Figure 5 with a steeper slope at intermediate values. Nutrition rates are the same as they were kept at the clinically specified levels. Table 10 shows the p-values comparing the CDFs in Figure 5 . The clinical data to STAR rerun (column 1) shows the impact of timing or delayed/missed clinical measurements, as well as any rounding of the insulin interventions given. The second column indicates that using a more relevant stochastic model (Model 5) would have yielded a different set of insulin interventions, as seen in Table 8 , with lesser impact on BG likely due to trial length. The p -value of 0.91 between clinical data and resimulation results results from small increases in nutrition in re-simulations, based on increases in nutrition rates at lower BG values with no insulin being given, and is thus not 1.0. Table 10 -p-values using Wilcoxon rank sum test for equal medians. The p-value is the probability of observing a difference between the two data set medians as large as the difference observed here, or larger, assuming the hypothesis that the medians are equal.
P-values
DISCUSSION
This proof-of-concept trial is the first attempt to use the STAR approach outside the neonatal ICU (NICU) [25] and initial STAR trials ongoing in Christchurch ICU. One important result is that no severe hypoglycemia (BG < 40 mg/dL) occurred during this 24-hour clinical pilot trial. The minimum BG recorded was 63 mg/dL for Patient 1, with the next lowest at 82 mg/dL for Patient 2. Hence, there was no apparent risk of hypoglycemia, despite the unexpected high metabolic variability in SI observed.
The control was generally consistent across different, highly variable patients, as seen in Figure 3 .
However, the time spent at the 125 mg/dL target was relatively low due primarily to patient variability, high initial BG levels, and the short 24-hour total trial length. The fact that relatively long times in the desired glycemic bands (110-140 mg/dL in particular) were achieved supports the overall efficacy of this approach.
During the pilot trial, several patients displayed relatively large variability in insulin sensitivity, as shown by example for Patient 3 in Figure 6 . This variability exceeded the predictions of the cohortbased stochastic model and made accurate model-based forecasting, prediction and TGC more difficult. As a result, forecasts within prediction ranges were lower than expected ( Table 5 ). New stochastic models using clinical data specific to cardiac-surgery patients and for specific days post-surgery were much more effective in capturing this variability. It should also be noted that Patient 3 was immediate post-surgery, and this greater variability should perhaps be expected based on the re-analysis done with modified stochastic models. The improved forecasting in Table 6 for models using only 1-2 days of stay indicates that the greater variability seen here may be reflective of patients early in their stay being more variable. Earlier analyses [5] showed similar variability for a similar cohort over all days, but did not examine specific patients or days of stay. Equally, these 9 patients may simply have been more variable. The main goal of this pilot trial was to assess performance, safety and implementation issues. In particular, several features were adapted for clinical implementation and to reduce nursing effort, which was higher than desired. Three-hour measurement periods would be desirable to further reduce nursing staff effort. However, as patients were not glycemically stable in this pilot trial such an improvement would not have been effective here. Longer trials over more patients would see improvements if variability declined over time or if patients were less variable than the small subset in this pilot trial.
Equally, longer intervals can be implemented using improved stochastic models and accepting a lower level of control than targeted in this study. In particular, stochastic bounds can be used to maximize the likelihood of BG in a desired range, as opposed to a specific target, as has been done in NICU STAR studies [25] . This approach and other changes will be implemented and tested going forward.
In addition, when insulin infusions are used with hourly measurement, a measurable fraction of the administered insulin has no time to act before the end of the hour, and insulin "cycling" may occur.
Insulin "cycling" is defined here as periodic insulin rate evolution characterized by a progressive increase followed by a sudden decrease. This behavior is illustrated by Patient 6 in Figure 7 . These cycles occur in part due to clinically imposed limits in increasing insulin infusion rates (for safety) in Insulin sensitivity response to increasing BG. However, because a given infusion rate's full effect is not seen before the end of one hour (~55%) the controller using a model for hour-to-hour control may underestimate its effect and thus increase the infusion rate further. This effect is exacerbated at the relatively low (or zero) insulin infusion rates seen in this study. The presence of higher rates of insulin infusion may allow the model to make a more accurate estimation of patient state by reducing the impact of endogenous insulin production, for which the model must assume a population constant [23] as it is currently not measurable in clinical real-time. Hence, longer time intervals might be better when using infusions of insulin compared to bolus administration in SPRINT [16] . Clinical results show that the controller is effective and safe, resulting in no hypoglycemic event (BG < 40 mg/dL) for the nine patients included in the pilot trial. Among the 205 BG measurements, only one was below 72 mg/dL (63 mg/dL). Controlled BG levels were tightly distributed. However, the pilot trial length of 24-hours was not designed to show long-term steady state control. Thus, despite every patient reaching 125 mg/dL, median BG values were slightly higher than the 125 mg/dL target.
An important result was the observation that some patients were significantly more variable in their insulin sensitivity (SI) than expected from stochastic cohort models using all patient days of stay. New stochastic models were created to better account for this variability. The application of a stochastic model using only the initial 1-2 days of stay would have resulted in different, more continuous insulin interventions and better forecasting. Ongoing next-generation pilot trials are thus expected to account for this variability directly and should thus reduce the measurement rate seen here as a result.
The overall results show tight, very safe control for post-cardiac surgery patients who exhibit significantly enhanced variability. Thus, the fundamental stochastic targeted (STAR) concept has been shown to be safe and effective when adapted, within its control framework, for an insulin-only approach in this Belgian ICU. Specific issues to be modified to enhance performance and usability were identified in this short, proof-of-concept trial, and will be implemented in a next generation pilot trial. The insulin sensitivity is the critical parameter in predicting the outcome of an insulin intervention. As insulin sensitivity is relatively variable hourly, modeling the changes in insulin sensitivity is quite important to improve assessment of the patient's insulin response, and thus to allow more accurately targeted control.
The goal of the stochastic model is to describe the hourly variations of the insulin sensitivity, based on clinically observed insulin sensitivity variations in ICU population data. First, clinical data (blood glucose, insulin and nutrition inputs) are used to identify hourly insulin sensitivity values using the glucose-insulin system model (A-1) [21] . If insulin sensitivity at hour n+1 and at hour n are denoted respectively by , +1 and , , the distribution of the hourly changes in , ( , = , , +1 = ), can be assessed (Figure 8, left panel) . Finally, a probability density of insulin sensitivity at hour n+1 ( , +1 ) taking on a value can be calculated by knowing insulin sensitivity at hour n ( , ), using identified variations from clinical data. This probability density function, ( , +1 = | , = ), defined the stochastic model. An example is illustrated on the right panel in Figure 8 . The stochastic insulin model can then be used to forecast likely blood glucose outcomes for a given intervention (a given insulin infusion), using the model defined by Equations (1) to (3). This approach, illustrated in Figure 9 , allows the optimization of prediction and ensures safety, especially from hypoglycemia. For a given insulin intervention, an output BG distribution can be forecast using the model of glucose-insulin system.
Figure 9 -Distribution of BG outcomes based on the stochastic model for insulin sensitivity variations
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